Differences between graft product and donor side effects following bone marrow or stem cell donation


Creative Commons License

Favre G., BEKSAÇ M., Bacigalupo A., Ruutu T., Nagler A., Gluckman E., ...Daha Fazla

BONE MARROW TRANSPLANTATION, cilt.32, sa.9, ss.873-880, 2003 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 32 Sayı: 9
  • Basım Tarihi: 2003
  • Doi Numarası: 10.1038/sj.bmt.1704245
  • Dergi Adı: BONE MARROW TRANSPLANTATION
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.873-880
  • Anahtar Kelimeler: allogeneic hematopoietic stem cell transplantation, peripheral blood stem cells, granulocyte colony-stimulating factor, leukapheresis, donor safety, PERIPHERAL-BLOOD STEM, COLONY-STIMULATING FACTOR, PROGENITOR-CELL, ALLOGENEIC TRANSPLANTATION, RANDOMIZED-TRIAL, EUROPEAN-GROUP, MOBILIZATION, LEUKEMIA, EXPERIENCE, FILGRASTIM
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Ankara Üniversitesi Adresli: Evet

Özet

We report graft product stem cell yields and donor safety results of a randomized multicenter study comparing allogeneic peripheral blood stem cell (PBSC) PBSC transplantation with BM trans plantation. Matched HLA-identical sibling donors (n = 329) were randomized to filgrastim-mobilized PBSC or bone marrow (BM) donation groups. Median yields per kg recipient weight of CD34(+) cells, T cells, and natural killer (NK) cells, respectively, were approximately two-fold, eight-fold, and greater than eight-fold in the PBSC group than in the BM group (CD34(+) cells, 5.8 x 10(6)/kg vs 2.7 x 10(6)/kg; T cells, 300.1 x 10(6)/kg vs 35.7 x 10(6)/kg; NK cells, 28.2 x 10(6)/kg vs 3.6 x 10(6)/kg; P < 0.001 for each). In connection with the cell collection procedures, PBSC donors spent a shorter median time in hospital than BM donors (0 vs 2 days; median difference -2 days, 95% CI -2 to 2) and had fewer median days of restricted activity (2 vs 6 days; median difference -3 days, 95% CI -4 to 2). Overall, 65% of PBSC donors and 57% of BM donors reported at least one adverse event (AE), most of which were transient, mild-moderate in severity, and without clinical sequelae. PBSC donors experienced predominantly filgrastim-related AEs, while BM donors experienced predominantly harvest-related AEs.